Región Metropolitana de Santiago
Este organismo compró $35.329.096.472 en 11.633 órdenes de compra , sobre todo en Medicamentos y productos farmacéuticos / Medicamentos anti infecciosos / Medicamentos antivirales y le compró principalmente a Sur Medical SpA.
238 meses con data · color por monto (sqrt scale)
| Año | Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sep | Oct | Nov | Dic | Total año |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
| $1367,1 M |
| 2025 | $2402,7 M |
| 2024 | $2107,2 M |
| 2023 | $2816,8 M |
| 2022 | $1338 M |
| 2021 | $1018,6 M |
| 2020 | $888,8 M |
| 2019 | $901,2 M |
| 2018 | $1471,2 M |
| 2017 | $786,1 M |
| 2016 | $14,2 mil M |
| 2015 | $919,8 M |
| 2014 | $428,8 M |
| 2013 | $340,8 M |
| 2012 | $359,5 M |
| 2011 | $701,4 M |
| 2010 | $913,7 M |
| 2009 | $590,7 M |
| 2008 | $571,8 M |
| 2007 | $1180,7 M |
| 2006 | $34,7 M |
238 períodos con data
Fuente: Agregaciones mensuales sobre OCs ingeridas
10 contrapartes
Fuente: Tabla top_contrapartes_comprador
| Código | Fecha | Proveedor | Estado | Monto |
|---|---|---|---|---|
| 2980-395-AG25 | 21-10-2025 | Novartis Chile S.A. | Recepcion Conforme | $5.395.291 |
| 2980-396-AG25 | 21-10-2025 | Laboratorio C&d Pharma Limitada | Recepcion Conforme | $3.927.000 |
| 2980-397-AG25 | 21-10-2025 | Terafarma Lab Limitada | Recepcion Conforme | $508.368 |
| 2980-361-AG25 | 20-10-2025 | Laboratorio Aconfar Chile Limitada | Recepcion Conforme | $565.488 |
| 2980-363-AG25 | 20-10-2025 | Astrazeneca S.A. | Recepcion Conforme | $6.129.404 |
| 2980-364-AG25 | 20-10-2025 | Pharmaxpress SpA | Recepcion Conforme | $2.829.820 |
| 2980-366-AG25 | 20-10-2025 | Laboratorios Andromaco S.A. | Recepcion Conforme | $6.130.880 |
| 2980-367-AG25 | 20-10-2025 | Astrazeneca S.A. | Recepcion Conforme | $6.129.404 |
| 2980-368-AG25 | 20-10-2025 | Gador Limitada | Recepcion Conforme | $2.623.950 |
| 2980-369-AG25 | 20-10-2025 | Abbvie Productos Farmaceuticos Limitada | Recepcion Conforme | $1.342.958 |
| 2980-370-AG25 | 20-10-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $547.352 |
| 2980-371-AG25 | 20-10-2025 | Novartis Chile S.A. | Recepcion Conforme | $1.854.325 |
| 2980-372-AG25 | 20-10-2025 | Novartis Chile S.A. | Recepcion Conforme | $5.395.291 |
| 2980-373-AG25 | 20-10-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $544.217 |
| 2980-374-AG25 | 20-10-2025 | Astrazeneca S.A. | Recepcion Conforme | $1.897.762 |
| 2980-375-AG25 | 20-10-2025 | Novartis Chile S.A. | Recepcion Conforme | $5.596.877 |
| 2980-377-AG25 | 20-10-2025 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $2.447.663 |
| 2980-378-AG25 | 20-10-2025 | Novofarma Service S.A. | Recepcion Conforme | $4.760.095 |
| 2980-360-AG25 | 16-10-2025 | Pharmaxpress SpA | Recepcion Conforme | $356.143 |
| 2980-376-AG25 | 16-10-2025 | Novartis Chile S.A. | Recepcion Conforme | $6.428.142 |
| 2980-383-AG25 | 16-10-2025 | Synthon Chile Limitada | Recepcion Conforme | $2.037.935 |
| 2980-385-AG25 | 16-10-2025 | Varifarma Chile SpA | Recepcion Conforme | $1.280.916 |
| 2980-386-AG25 | 16-10-2025 | Varifarma Chile SpA | Recepcion Conforme | $4.138.344 |
| 2980-387-AG25 | 16-10-2025 | Productos Farmoquimicos Roche Limitada | Recepcion Conforme | $5.617.485 |
| 2980-388-AG25 | 16-10-2025 | Gador Limitada | Recepcion Conforme | $4.209.749 |
| 2980-351-AG25 | 15-10-2025 | Bayer S.A. | Recepcion Conforme | $6.735.909 |
| 2980-354-SE25 | 15-10-2025 | Fundacion Dr Jorge Perez Rifo | Recepcion Conforme | $4.230.815 |
| 2980-355-SE25 | 15-10-2025 | Fundacion Dr Jorge Perez Rifo | Recepcion Conforme | $963.826 |
| 2980-356-SE25 | 15-10-2025 | Fundacion Dr Jorge Perez Rifo | Recepcion Conforme | $147.418 |
| 2980-357-SE25 | 15-10-2025 | Fundacion Dr Jorge Perez Rifo | Recepcion Conforme | $12.777.221 |
